SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Farnier, M.
Right arrow Articles by Maigret, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Farnier, M.
Right arrow Articles by Maigret, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Efficacy of Atorvastatin Compared With Simvastatin in Patients With Hypercholesterolemia

Michel Farnier

Point Médical, Dijon

Jean-Jacques Portal

Parke Davis, Courbevoie, France

Pascal Maigret

Parke Davis, Courbevoie, France

Background: Atorvastatin, a new enantiomerically pure synthetic statin, has shown a marked low-density lipoprotein (LDL) cholesterol reduction at doses ranging from 10 to 80 mg/d. This trial was designed to compare the efficacy of atorvastatin 10 mg with simvastatin 10 mg and 20 mg, the latter dose being commonly used in some countries.

Methods and Results: A parallel group, randomized, PROBE, multicenter study was con ducted to compare the efficacy of 10 mg/d atorvastatin with that of 10 mg/d simvastatin and 20 mg/d simvastatin in patients with primary hypercholesterolemia. After a 6-week diet- placebo lead-in period, 272 patients with LDL cholesterol ≥ 160 mg/dL and triglycerides ≤ 300 mg/dL were randomized to 6 weeks of treatment with atorvastatin 10 mg (109 patients), simvastatin 20 mg (109 patients), or simvastatin 10 mg (54 patients). In the main analysis, which tested the equivalence of atorvastatin 10 mg and simvastatin 20 mg, the mean percent change in LDL cholesterol for atorvastatin 10 mg (-37.0%) was greater than and not equiva lent to simvastatin 20 mg (-33.8%). In the secondary analysis, which compared the efficacy of atorvastatin 10 mg with that of simvastatin 10 mg, the mean decrease in LDL cholesterol was significantly greater (P < .001) for atorvastatin 10 mg than for simvastatin 10 mg (-37.0% vs. -28.9%). The two drugs were well tolerated, with an incidence of clinical and biochemical side effects similar among the 3 treatment groups.

Conclusion: In primary hypercholesterolemia, atorvastatin 10 mg was more effective and nonequivalent to simvastatin 20 mg and significantly more effective than simvastatin 10 mg for reducing LDL cholesterol levels.

Key Words: atorvastatin • simvastatin • HMG-CoA reductase inhibitors • hypercholesterolemia.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 5, No. 1, 27-32 (2000)
DOI: 10.1177/107424840000500104


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Mayo Clin Proc.Home page
R. A. Krasuski, D. Doeppenschmidt, J. S. Henry, P. B. Smith, J. Adinaro, B. Rachel, and C. M. Thompson
Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study
Mayo Clin. Proc., September 1, 2005; 80(9): 1163 - 1168.
[Abstract] [PDF]


Home page
StrokeHome page
D. Woo, B. M. Kissela, J. C. Khoury, L. R. Sauerbeck, M. A. Haverbusch, J. P. Szaflarski, J. M. Gebel, A. M. Pancioli, E. C. Jauch, A. Schneider, et al.
Hypercholesterolemia, HMG-CoA Reductase Inhibitors, and Risk of Intracerebral Hemorrhage: A Case-Control Study
Stroke, June 1, 2004; 35(6): 1360 - 1364.
[Abstract] [Full Text] [PDF]



Advertisement